Literature DB >> 21762664

Cathelicidin signaling via the Toll-like receptor protects against colitis in mice.

Hon Wai Koon1, David Q Shih, Jeremy Chen, Kyriaki Bakirtzi, Tressia C Hing, Ivy Law, Samantha Ho, Ryan Ichikawa, Dezheng Zhao, Hua Xu, Richard Gallo, Paul Dempsey, Genhong Cheng, Stephan R Targan, Charalabos Pothoulakis.   

Abstract

BACKGROUND & AIMS: Cathelicidin (encoded by Camp) is an antimicrobial peptide in the innate immune system. We examined whether macrophages express cathelicidin in colons of mice with experimental colitis and patients with inflammatory bowel disease, and we investigated its signaling mechanisms.
METHODS: Quantitative, real-time, reverse-transcription polymerase chain reaction (PCR), bacterial 16S PCR, immunofluorescence, and small interfering RNA (siRNA) analyses were performed. Colitis was induced in mice using dextran sulfate sodium (DSS); levels of cathelicidin were measured in human primary monocytes.
RESULTS: Expression of cathelicidin increased in the inflamed colonic mucosa of mice with DSS-induced colitis compared with controls. Cathelicidin expression localized to mucosal macrophages in inflamed colon tissues of patients and mice. Exposure of human primary monocytes to Escherichia coli DNA induced expression of Camp messenger RNA, which required signaling by extracellular signal-regulated kinase (ERK); expression was reduced by siRNAs against Toll-like receptor (TLR)9 and MyD88. Intracolonic administration of bacterial DNA to wild-type mice induced expression of cathelicidin in colons of control mice and mice with DSS-induced colitis. Colon expression of cathelicidin was significantly reduced in TLR9(-/-) mice with DSS-induced colitis. Compared with wild-type mice, Camp(-/-) mice developed a more severe form of DSS-induced colitis, particularly after intracolonic administration of E coli DNA. Expression of cathelicidin from bone marrow-derived immune cells regulated DSS induction of colitis in transplantation studies in mice.
CONCLUSIONS: Cathelicidin protects against induction of colitis in mice. Increased expression of cathelicidin in monocytes and experimental models of colitis involves activation of TLR9-ERK signaling by bacterial DNA. This pathway might be involved in the pathogenesis of ulcerative colitis.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762664      PMCID: PMC3199285          DOI: 10.1053/j.gastro.2011.06.079

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

1.  Antimicrobial peptides of multicellular organisms.

Authors:  Michael Zasloff
Journal:  Nature       Date:  2002-01-24       Impact factor: 49.962

Review 2.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

3.  Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NF-kappaB-independent pathway.

Authors:  Mahmood Akhtar; James L Watson; Aisha Nazli; Derek M McKay
Journal:  FASEB J       Date:  2003-07       Impact factor: 5.191

4.  TLR9 mRNA expression is upregulated in patients with active ulcerative colitis.

Authors:  Fausto Sánchez-Muñoz; Gabriela C Fonseca-Camarillo; Marco A Villeda-Ramirez; Rafael Barreto-Zuniga; Rafael Bojalil; Aarón Domínguez-Lopez; Misael Uribe; Jesus K Yamamoto-Furusho
Journal:  Inflamm Bowel Dis       Date:  2010-08       Impact factor: 5.325

5.  Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse.

Authors:  R L Gallo; K J Kim; M Bernfield; C A Kozak; M Zanetti; L Merluzzi; R Gennaro
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

6.  Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls.

Authors:  B Kleessen; A J Kroesen; H J Buhr; M Blaut
Journal:  Scand J Gastroenterol       Date:  2002-09       Impact factor: 2.423

7.  Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells.

Authors:  Jürgen Schauber; Konrad Iffland; Susanne Frisch; Theodor Kudlich; Bernd Schmausser; Matthias Eck; Thomas Menzel; Andrea Gostner; Hardi Lührs; Wolfgang Scheppach
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

8.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis.

Authors:  Daniel Rachmilewitz; Kyoko Katakura; Fanny Karmeli; Tomoko Hayashi; Constantin Reinus; Bernard Rudensky; Shizuo Akira; Kiyoshi Takeda; Jongdae Lee; Kenji Takabayashi; Eyal Raz
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways.

Authors:  J Schauber; C Svanholm; S Termén; K Iffland; T Menzel; W Scheppach; R Melcher; B Agerberth; H Lührs; G H Gudmundsson
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 10.  Epithelial antimicrobial peptides in host defense against infection.

Authors:  R Bals
Journal:  Respir Res       Date:  2000-10-20
View more
  51 in total

1.  Hepcidin expression in colon during trinitrobenzene sulfonic acid-induced colitis in rats.

Authors:  Érica Martins Ferreira Gotardo; Gilberto de Almeida Ribeiro; Thayane Rodrigues Leite Clemente; Camila Henrique Moscato; Renata Bortolin Guerra Tomé; Thalita Rocha; José Pedrazzoli; Marcelo Lima Ribeiro; Alessandra Gambero
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  Heterogeneity across the murine small and large intestine.

Authors:  Rowann Bowcutt; Ruth Forman; Maria Glymenaki; Simon Richard Carding; Kathryn Jane Else; Sheena Margaret Cruickshank
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

3.  MUC2 Mucin and Butyrate Contribute to the Synthesis of the Antimicrobial Peptide Cathelicidin in Response to Entamoeba histolytica- and Dextran Sodium Sulfate-Induced Colitis.

Authors:  Eduardo R Cobo; Vanessa Kissoon-Singh; France Moreau; Ravi Holani; Kris Chadee
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

Review 4.  The role of the antimicrobial peptide cathelicidin in renal diseases.

Authors:  Milan Chromek
Journal:  Pediatr Nephrol       Date:  2014-08-27       Impact factor: 3.714

Review 5.  Role of genetics in the diagnosis and prognosis of Crohn's disease.

Authors:  Epameinondas V Tsianos; Konstantinos H Katsanos; Vasileios E Tsianos
Journal:  World J Gastroenterol       Date:  2011-12-28       Impact factor: 5.742

Review 6.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

7.  Differentiating functional roles of gene expression from immune and non-immune cells in mouse colitis by bone marrow transplantation.

Authors:  Hon Wai Koon; Samantha Ho; Michelle Cheng; Ryan Ichikawa; Charalabos Pothoulakis
Journal:  J Vis Exp       Date:  2012-10-01       Impact factor: 1.355

8.  Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study.

Authors:  Tara Raftery; Adrian R Martineau; Claire L Greiller; Subrata Ghosh; Deirdre McNamara; Kathleen Bennett; Jon Meddings; Maria O'Sullivan
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

Review 9.  Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis.

Authors:  Avijit Ray; Bonnie N Dittel
Journal:  Immunology       Date:  2015-09-07       Impact factor: 7.397

Review 10.  Cathelicidin a potential therapeutic peptide for gastrointestinal inflammation and cancer.

Authors:  Jimmy Yip Chuen Chow; Zhi Jie Li; William Ka Kei Wu; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.